Public Speaking Anxiety Clinical Trial
— VRanxOfficial title:
Virtual Reality Based Cognitive Behavioral Therapy for Public Speaking Anxiety
NCT number | NCT06214039 |
Other study ID # | VRanx_001 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | February 14, 2024 |
Est. completion date | May 2026 |
This study aims to examine the efficacy of exposure using virtual reality (VR) for public speaking anxiety in young adults in two treatment arms: a one-session VR exposure therapy with a 4-week online transition intervention versus a three-session VR exposure therapy with a 4-week online transition intervention. Previous studies have demonstrated that one-session therapy (OST) is comparable to prolonged exposure-based therapies in terms of effectively reducing public speaking anxiety. Moreover, VR offers many benefits compared to in-person exposure, namely the ability to produce anxiety-evoking stimuli without having to leave the therapist's room. However, OST VR exposure has not been directly compared to prolonged VR exposure and not for public speaking anxiety.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | May 2026 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 30 Years |
Eligibility | Inclusion Criteria: - aged 18-30 and studying in higher education; - experiencing a significant level of public speaking anxiety (60+ on PSAS); - able to use a computer and have access to the internet for the duration of the study; - able to understand, write and speak in Lithuanian; - available to participate in one or three in-person intervention sessions and can devote the time to participate in a 4-week online program following the intervention sessions. Exclusion Criteria: - a history of seizures or a history of epilepsy; - other significant medical conditions that would prevent them from participating in the program; - high levels of depression (Patient Health Questionnaire-9 rating of 15 and above and mentions of suicidal ideation) or other significant psychiatric conditions that would interfere with participation in the program; - a tendency to have extreme seasickness reactions or a history of adverse physical reactions to virtual reality experiences or difficulty with or lack of stereoscopic vision; - current involvement in other psychological interventions such as psychological counseling or psychotherapy; - use of psychoactive drugs, unless stable for three months; - current participation in other programs aimed at reducing public speaking anxiety. |
Country | Name | City | State |
---|---|---|---|
Lithuania | Vilnius University | Vilnius |
Lead Sponsor | Collaborator |
---|---|
Vilnius University | Linkoeping University, Stockholm University, Thomas More University of Applied Sciences |
Lithuania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Subjective Units of Distress (SUD) | Each measure will be rated on a scale from 0 to 100. Higher number indicates higher distress. | Pre-intervention, immediately after the intervention | |
Primary | Public Speaking Anxiety Scale (PSAS), (Bartholomay & Houlihan, 2016). | Canonical total score will be used. Measure is self-rated, online. The scale consists of 17 self-report statements measured on a Likert-type scale ranging from 1 "not at all", to 5 "extremely". A higher score indicates higher levels of experienced public speaking anxiety. | Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment | |
Secondary | Liebowitz Social Anxiety Scale - Self-Report (LSAS-SR), (Liebowitz, 2003; Rytwinski et al., 2009) | Canonical total score will be used. Measure is self-rated, online. Items are rated using 4-point Likert scales ranging from 0 to 3. A higher score indicates more severe symptoms. | Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment | |
Secondary | Brief Fear of Negative Evaluation Scale (BFNE), (Leary, 1983) | Canonical total score will be used. Measure is self-rated, online. The BFNE is a 12-item, 5-point Likert-type scale, ranging from 1 ""not at all" to 5 "extremely". Higher scores indicate higher fear. | Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment | |
Secondary | Igroup Presence Questionnaire (IPQ) | Canonical total score will be used. Measure is self-rated, online. Each of the 14 items is rated on a 7-point Likert scale and the score is calculated by summing the ratings for each item. | Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment | |
Secondary | Patient health questionnaire - 9 (PHQ-9), (Spitzer et al., 1999) | Canonical total score will be used. Measure is self-rated, online. PHQ-9 consists of 9 items that are rated depending on how often the symptoms were bothersome using a 4-point scale, ranging from 0 "not at all" to 3 "nearly every day". The ratings are summed for the total score and higher scores indicates more severe depression symtpoms. | Pre-treatment, mid-treatment, immediately after the intervention, 3 and 12 months post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00000370 -
Treatment of Social Phobia
|
N/A |